BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15121765)

  • 1. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
    Kolh P; Rolin S; Tchana-Sato V; Pétein M; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Masereel B; D'Orio V; Dogne JM
    Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):53-73. PubMed ID: 16516810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
    Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.
    Tchana-Sato V; Dogné JM; Lambermont B; Ghuysen A; Magis D; Morimont P; Hanson J; D'Orio V; Limet R; Kolh P
    Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):82-95. PubMed ID: 16303607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
    Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
    J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock.
    Lambermont B; Kolh P; Ghuysen A; Segers P; Dogné JM; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; D'Orio V
    Shock; 2004 Jan; 21(1):45-51. PubMed ID: 14676683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
    Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
    Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
    Ghuysen A; Dogné JM; Chiap P; Rolin S; Masereel B; Lambermont B; Kolh P; Tchana-Sato V; Hanson J; D'Orio V
    Cardiovasc Drug Rev; 2005; 23(1):1-14. PubMed ID: 15867944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation.
    Nuttall GA; Murray MJ; Bowie EJ
    Anesthesiology; 1991 Jan; 74(1):138-45. PubMed ID: 1824742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
    Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
    Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model.
    Iglesias G; Zeigler ST; Lentz CW; Traber DL; Herndon DN
    J Am Coll Surg; 1994 Aug; 179(2):187-92. PubMed ID: 8044389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of right ventricular-pulmonary vascular coupling in a porcine model of progressive pressure overloading.
    Ghuysen A; Lambermont B; Kolh P; Tchana-Sato V; Magis D; Gerard P; Mommens V; Janssen N; Desaive T; D'Orio V
    Shock; 2008 Feb; 29(2):197-204. PubMed ID: 17693928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor.
    Lambermont B; Kolh P; Dogné JM; Ghuysen A; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; Limet R; D'Orio V
    Arch Physiol Biochem; 2003 Jul; 111(3):217-23. PubMed ID: 14972743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs.
    Conzen PF; Habazettl H; Gutmann R; Hobbhahn J; Goetz AE; Peter K; Brendel W
    Anesth Analg; 1989 Jan; 68(1):25-31. PubMed ID: 2910134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
    Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.